Hemogenyx Pharmaceuticals Statistics

Total Valuation

LON:HEMO has a market cap or net worth of GBP 8.14 million. The enterprise value is 10.56 million.

Market Cap	8.14M
Enterprise Value	10.56M

Important Dates

The next estimated earnings date is Friday, June 27, 2025.

Earnings Date	Jun 27, 2025
Ex-Dividend Date	n/a

Share Statistics

LON:HEMO has 4.59 million shares outstanding. The number of shares has increased by 16.95% in one year.

Current Share Class	4.59M
Shares Outstanding	4.59M
Shares Change (YoY)	+16.95%
Shares Change (QoQ)	+15.27%
Owned by Insiders (%)	12.06%
Owned by Institutions (%)	68.32%
Float	4.01M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	9.54
P/TBV Ratio	19.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.88
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.54

Financial Position

The company has a current ratio of 0.72, with a Debt / Equity ratio of 3.07.

Current Ratio	0.72
Quick Ratio	0.14
Debt / Equity	3.07
Debt / EBITDA	n/a
Debt / FCF	-0.63
Interest Coverage	-19.80

Financial Efficiency

Return on equity (ROE) is -309.56% and return on invested capital (ROIC) is -73.03%.

Return on Equity (ROE)	-309.56%
Return on Assets (ROA)	-65.15%
Return on Invested Capital (ROIC)	-73.03%
Return on Capital Employed (ROCE)	-176.13%
Revenue Per Employee	n/a
Profits Per Employee	-351,199
Employee Count	16
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -70.06% in the last 52 weeks. The beta is 0.67, so LON:HEMO's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	-70.06%
50-Day Moving Average	180.03
200-Day Moving Average	372.51
Relative Strength Index (RSI)	42.34
Average Volume (20 Days)	46,510

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-5.38M
Pretax Income	-5.63M
Net Income	-5.62M
EBITDA	-5.15M
EBIT	-5.38M
Earnings Per Share (EPS)	-1.70

Full Income Statement

Balance Sheet

The company has 159,265 in cash and 2.62 million in debt, giving a net cash position of -2.46 million or -0.54 per share.

Cash & Cash Equivalents	159,265
Total Debt	2.62M
Net Cash	-2.46M
Net Cash Per Share	-0.54
Equity (Book Value)	853,494
Book Value Per Share	0.26
Working Capital	-319,605

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.14 million and capital expenditures -13,285, giving a free cash flow of -4.15 million.

Operating Cash Flow	-4.14M
Capital Expenditures	-13,285
Free Cash Flow	-4.15M
FCF Per Share	-0.90

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:HEMO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.95%
Shareholder Yield	n/a
Earnings Yield	-69.01%
FCF Yield	-51.01%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 13, 2024. It was a reverse split with a ratio of 0.0025.

Last Split Date	Dec 13, 2024
Split Type	Reverse
Split Ratio	0.0025

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a